Hemophilia A Drug Industry: Global Market Opportunities and Forecast 2021-2027
- Category: Healthcare
- Published Date: Dec 2021
- Publisher: GRD Survey
- Pages: 166
Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Hemophilia A Drug market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Hemophilia A Drug market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.
Segmented by Category
ATXF-8117
BAY-1093884
BIVV-001
BS-027125
Concizumab
CSL-689
Others
Segmented by End User/Segment
Clinic
Hospital
ASCs
Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia
Key manufacturers included in this survey
mAbxience SA
LFB SA
Immusoft Corp
Idogen AB
Green Cross Corp
Expression Therapeutics LLC
EpiVax Inc
Dimension Therapeutics Inc
DBV Technologies SA
CSL Ltd
Chugai Pharmaceutical Co Ltd
Catalyst Biosciences Inc
Bioverativ Inc
BioMarin Pharmaceutical Inc
Bayer AG
Segmented by Category
ATXF-8117
BAY-1093884
BIVV-001
BS-027125
Concizumab
CSL-689
Others
Segmented by End User/Segment
Clinic
Hospital
ASCs
Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia
Key manufacturers included in this survey
mAbxience SA
LFB SA
Immusoft Corp
Idogen AB
Green Cross Corp
Expression Therapeutics LLC
EpiVax Inc
Dimension Therapeutics Inc
DBV Technologies SA
CSL Ltd
Chugai Pharmaceutical Co Ltd
Catalyst Biosciences Inc
Bioverativ Inc
BioMarin Pharmaceutical Inc
Bayer AG
Table of Contents
1 Product Introduction and Overview
1.1 Product Definition
1.2 Product Specification
1.3 Global Market Overview
1.3.1 Global Hemophilia A Drug Market Status and Forecast (2016-2027)
1.3.2 Global Hemophilia A Drug Sales Value CAGR by Region
1.4 Market Drivers, Inhibitors
1.4.1 Market Drivers
1.4.2 Market Inhibitors
1.4.3 COVID-19 Impact Analysis
2 Global Hemophilia A Drug Supply by Company
2.1 Global Hemophilia A Drug Sales Volume by Company
2.2 Global Hemophilia A Drug Sales Value by Company
2.3 Global Hemophilia A Drug Price by Company
2.4 Hemophilia A Drug Production Location and Sales Area of Main Manufacturers
2.5 Trend of Concentration Rate
3 Global and Regional Hemophilia A Drug Market Status by Category
3.1 Hemophilia A Drug Category Introduction
3.1.1 ATXF-8117
3.1.2 BAY-1093884
3.1.3 BIVV-001
3.1.4 BS-027125
3.1.5 Concizumab
3.1.6 CSL-689
3.1.7 Others
3.2 Global Hemophilia A Drug Market by Category
3.2.1 Global Hemophilia A Drug Sales Volume by Category (2016-2021)
3.2.2 Global Hemophilia A Drug Sales Value by Category (2016-2021)
3.2.3 Global Hemophilia A Drug Price by Category (2016-2021)
3.3 North America: by Category
3.4 Europe: by Category
3.5 Asia Pacific: by Category
3.6 Central & South America: by Category
3.7 Middle East & Africa: by Category
4 Global and Regional Hemophilia A Drug Market Status by End User/Segment
4.1 Hemophilia A Drug Segment by End User/Segment
4.1.1 Clinic
4.1.2 Hospital
4.1.3 ASCs
4.2 Global Hemophilia A Drug Market by End User/Segment
4.2.1 Global Hemophilia A Drug Sales Volume by End User/Segment (2016-2021)
4.2.2 Global Hemophilia A Drug Sales Value by End User/Segment (2016-2021)
4.2.3 Global Hemophilia A Drug Price by End User/Segment (2016-2021)
4.3 North America: by End User/Segment
4.4 Europe: by End User/Segment
4.5 Asia Pacific: by End User/Segment
4.6 Central & South America: by End User/Segment
4.7 Middle East & Africa: by End User/Segment
5 Global Hemophilia A Drug Market Status by Region
5.1 Global Hemophilia A Drug Market by Region
5.1.1 Global Hemophilia A Drug Sales Volume by Region
5.1.2 Global Hemophilia A Drug Sales Value by Region
5.2 North America Hemophilia A Drug Market Status
5.3 Europe Hemophilia A Drug Market Status
5.4 Asia Pacific Hemophilia A Drug Market Status
5.5 Central & South America Hemophilia A Drug Market Status
5.6 Middle East & Africa Hemophilia A Drug Market Status
6 North America Hemophilia A Drug Market Status
6.1 North America Hemophilia A Drug Market by Country
6.1.1 North America Hemophilia A Drug Sales Volume by Country (2016-2021)
6.1.2 North America Hemophilia A Drug Sales Value by Country (2016-2021)
6.2 United States
6.3 Canada
6.4 Mexico
7 Europe Hemophilia A Drug Market Status
7.1 Europe Hemophilia A Drug Market by Country
7.1.1 Europe Hemophilia A Drug Sales Volume by Country (2016-2021)
7.1.2 Europe Hemophilia A Drug Sales Value by Country (2016-2021)
7.2 Germany
7.3 France
7.4 UK
7.5 Italy
7.6 Russia
7.7 Spain
8 Asia Pacific Hemophilia A Drug Market Status
8.1 Asia Pacific Hemophilia A Drug Market by Country
8.1.1 Asia Pacific Hemophilia A Drug Sales Volume by Country (2016-2021)
8.1.2 Asia Pacific Hemophilia A Drug Sales Value by Country (2016-2021)
8.2 China
8.3 Japan
8.4 Korea
8.5 Southeast Asia
8.6 India
8.7 Australasia
9 Central & South America Hemophilia A Drug Market Status
9.1 Central & South America Hemophilia A Drug Market by Country
9.1.1 Central & South America Hemophilia A Drug Sales Volume by Country (2016-2021)
9.1.2 Central & South America Hemophilia A Drug Sales Value by Country (2016-2021)
9.2 Brazil
9.3 Argentina
9.4 Colombia
10 Middle East & Africa Hemophilia A Drug Market Status
10.1 Middle East & Africa Hemophilia A Drug Market by Country
10.1.1 Middle East & Africa Hemophilia A Drug Sales Volume by Country (2016-2021)
10.1.2 Middle East & Africa Hemophilia A Drug Sales Value by Country (2016-2021)
10.2 Iran
10.3 Israel
10.4 Turkey
10.5 South Africa
10.8 Saudi Arabia
11 Supply Chain and Manufacturing Cost Analysis
11.1 Supply Chain Analysis
11.2 Production Process Chart Analysis
11.3 Raw Materials and Key Suppliers Analysis
11.3.1 Raw Materials Introduction
11.3.2 Raw Materials Key Suppliers List
11.4 Hemophilia A Drug Manufacturing Cost Analysis
11.5 Hemophilia A Drug Sales Channel and Distributors Analysis
11.5.1 Hemophilia A Drug Sales Channel
11.5.2 Hemophilia A Drug Distributors
11.6 Hemophilia A Drug Downstream Major Buyers
12 Global Hemophilia A Drug Market Forecast by Category and by End User/Segment
12.1 Global Hemophilia A Drug Sales Volume and Sales Value Forecast (2022-2027)
12.2 Global Hemophilia A Drug Forecast by Category
12.2.1 Global Hemophilia A Drug Sales Volume Forecast by Category
12.2.2 Global Hemophilia A Drug Sales Value Forecast by Category
12.2.3 Global Hemophilia A Drug Price Forecast by Category
12.3 Global Hemophilia A Drug Forecast by End User/Segment
12.3.1 Global Hemophilia A Drug Sales Volume Forecast by End User/Segment
12.3.2 Global Hemophilia A Drug Sales Value Forecast by End User/Segment
12.3.3 Global Hemophilia A Drug Price Forecast by End User/Segment
13 Global Hemophilia A Drug Market Forecast by Region/Country
13.1 Global Hemophilia A Drug Market Forecast by Region (2022-2027)
13.1.1 Global Hemophilia A Drug Sales Volume Forecast by Region (2022-2027)
13.1.2 Global Hemophilia A Drug Sales Value Forecast by Region (2022-2027)
13.2 North America Market Forecast
13.3 Europe Market Forecast
13.4 Asia Pacific Market Forecast
13.5 Central & South America Market Forecast
13.6 Middle East & Africa Market Forecast
14 Key Participants Company Information
14.1 mAbxience SA
14.1.1 Company Information
14.1.2 Hemophilia A Drug Product Introduction
14.1.3 mAbxience SA Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.1.4 SWOT Analysis
14.2 LFB SA
14.2.1 Company Information
14.2.2 Hemophilia A Drug Product Introduction
14.2.3 LFB SA Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.2.4 SWOT Analysis
14.3 Immusoft Corp
14.3.1 Company Information
14.3.2 Hemophilia A Drug Product Introduction
14.3.3 Immusoft Corp Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.3.4 SWOT Analysis
14.4 Idogen AB
14.4.1 Company Information
14.4.2 Hemophilia A Drug Product Introduction
14.4.3 Idogen AB Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.4.4 SWOT Analysis
14.5 Green Cross Corp
14.5.1 Company Information
14.5.2 Hemophilia A Drug Product Introduction
14.5.3 Green Cross Corp Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.5.4 SWOT Analysis
14.6 Expression Therapeutics LLC
14.6.1 Company Information
14.6.2 Hemophilia A Drug Product Introduction
14.6.3 Expression Therapeutics LLC Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.6.4 SWOT Analysis
14.7 EpiVax Inc
14.7.1 Company Information
14.7.2 Hemophilia A Drug Product Introduction
14.7.3 EpiVax Inc Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.7.4 SWOT Analysis
14.8 Dimension Therapeutics Inc
14.8.1 Company Information
14.8.2 Hemophilia A Drug Product Introduction
14.8.3 Dimension Therapeutics Inc Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.8.4 SWOT Analysis
14.9 DBV Technologies SA
14.9.1 Company Information
14.9.2 Hemophilia A Drug Product Introduction
14.9.3 DBV Technologies SA Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.9.4 SWOT Analysis
14.10 CSL Ltd
14.10.1 Company Information
14.10.2 Hemophilia A Drug Product Introduction
14.10.3 CSL Ltd Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.10.4 SWOT Analysis
14.11 Chugai Pharmaceutical Co Ltd
14.12 Catalyst Biosciences Inc
14.13 Bioverativ Inc
14.14 BioMarin Pharmaceutical Inc
14.15 Bayer AG
15 Conclusion
16 Methodology
1 Product Introduction and Overview
1.1 Product Definition
1.2 Product Specification
1.3 Global Market Overview
1.3.1 Global Hemophilia A Drug Market Status and Forecast (2016-2027)
1.3.2 Global Hemophilia A Drug Sales Value CAGR by Region
1.4 Market Drivers, Inhibitors
1.4.1 Market Drivers
1.4.2 Market Inhibitors
1.4.3 COVID-19 Impact Analysis
2 Global Hemophilia A Drug Supply by Company
2.1 Global Hemophilia A Drug Sales Volume by Company
2.2 Global Hemophilia A Drug Sales Value by Company
2.3 Global Hemophilia A Drug Price by Company
2.4 Hemophilia A Drug Production Location and Sales Area of Main Manufacturers
2.5 Trend of Concentration Rate
3 Global and Regional Hemophilia A Drug Market Status by Category
3.1 Hemophilia A Drug Category Introduction
3.1.1 ATXF-8117
3.1.2 BAY-1093884
3.1.3 BIVV-001
3.1.4 BS-027125
3.1.5 Concizumab
3.1.6 CSL-689
3.1.7 Others
3.2 Global Hemophilia A Drug Market by Category
3.2.1 Global Hemophilia A Drug Sales Volume by Category (2016-2021)
3.2.2 Global Hemophilia A Drug Sales Value by Category (2016-2021)
3.2.3 Global Hemophilia A Drug Price by Category (2016-2021)
3.3 North America: by Category
3.4 Europe: by Category
3.5 Asia Pacific: by Category
3.6 Central & South America: by Category
3.7 Middle East & Africa: by Category
4 Global and Regional Hemophilia A Drug Market Status by End User/Segment
4.1 Hemophilia A Drug Segment by End User/Segment
4.1.1 Clinic
4.1.2 Hospital
4.1.3 ASCs
4.2 Global Hemophilia A Drug Market by End User/Segment
4.2.1 Global Hemophilia A Drug Sales Volume by End User/Segment (2016-2021)
4.2.2 Global Hemophilia A Drug Sales Value by End User/Segment (2016-2021)
4.2.3 Global Hemophilia A Drug Price by End User/Segment (2016-2021)
4.3 North America: by End User/Segment
4.4 Europe: by End User/Segment
4.5 Asia Pacific: by End User/Segment
4.6 Central & South America: by End User/Segment
4.7 Middle East & Africa: by End User/Segment
5 Global Hemophilia A Drug Market Status by Region
5.1 Global Hemophilia A Drug Market by Region
5.1.1 Global Hemophilia A Drug Sales Volume by Region
5.1.2 Global Hemophilia A Drug Sales Value by Region
5.2 North America Hemophilia A Drug Market Status
5.3 Europe Hemophilia A Drug Market Status
5.4 Asia Pacific Hemophilia A Drug Market Status
5.5 Central & South America Hemophilia A Drug Market Status
5.6 Middle East & Africa Hemophilia A Drug Market Status
6 North America Hemophilia A Drug Market Status
6.1 North America Hemophilia A Drug Market by Country
6.1.1 North America Hemophilia A Drug Sales Volume by Country (2016-2021)
6.1.2 North America Hemophilia A Drug Sales Value by Country (2016-2021)
6.2 United States
6.3 Canada
6.4 Mexico
7 Europe Hemophilia A Drug Market Status
7.1 Europe Hemophilia A Drug Market by Country
7.1.1 Europe Hemophilia A Drug Sales Volume by Country (2016-2021)
7.1.2 Europe Hemophilia A Drug Sales Value by Country (2016-2021)
7.2 Germany
7.3 France
7.4 UK
7.5 Italy
7.6 Russia
7.7 Spain
8 Asia Pacific Hemophilia A Drug Market Status
8.1 Asia Pacific Hemophilia A Drug Market by Country
8.1.1 Asia Pacific Hemophilia A Drug Sales Volume by Country (2016-2021)
8.1.2 Asia Pacific Hemophilia A Drug Sales Value by Country (2016-2021)
8.2 China
8.3 Japan
8.4 Korea
8.5 Southeast Asia
8.6 India
8.7 Australasia
9 Central & South America Hemophilia A Drug Market Status
9.1 Central & South America Hemophilia A Drug Market by Country
9.1.1 Central & South America Hemophilia A Drug Sales Volume by Country (2016-2021)
9.1.2 Central & South America Hemophilia A Drug Sales Value by Country (2016-2021)
9.2 Brazil
9.3 Argentina
9.4 Colombia
10 Middle East & Africa Hemophilia A Drug Market Status
10.1 Middle East & Africa Hemophilia A Drug Market by Country
10.1.1 Middle East & Africa Hemophilia A Drug Sales Volume by Country (2016-2021)
10.1.2 Middle East & Africa Hemophilia A Drug Sales Value by Country (2016-2021)
10.2 Iran
10.3 Israel
10.4 Turkey
10.5 South Africa
10.8 Saudi Arabia
11 Supply Chain and Manufacturing Cost Analysis
11.1 Supply Chain Analysis
11.2 Production Process Chart Analysis
11.3 Raw Materials and Key Suppliers Analysis
11.3.1 Raw Materials Introduction
11.3.2 Raw Materials Key Suppliers List
11.4 Hemophilia A Drug Manufacturing Cost Analysis
11.5 Hemophilia A Drug Sales Channel and Distributors Analysis
11.5.1 Hemophilia A Drug Sales Channel
11.5.2 Hemophilia A Drug Distributors
11.6 Hemophilia A Drug Downstream Major Buyers
12 Global Hemophilia A Drug Market Forecast by Category and by End User/Segment
12.1 Global Hemophilia A Drug Sales Volume and Sales Value Forecast (2022-2027)
12.2 Global Hemophilia A Drug Forecast by Category
12.2.1 Global Hemophilia A Drug Sales Volume Forecast by Category
12.2.2 Global Hemophilia A Drug Sales Value Forecast by Category
12.2.3 Global Hemophilia A Drug Price Forecast by Category
12.3 Global Hemophilia A Drug Forecast by End User/Segment
12.3.1 Global Hemophilia A Drug Sales Volume Forecast by End User/Segment
12.3.2 Global Hemophilia A Drug Sales Value Forecast by End User/Segment
12.3.3 Global Hemophilia A Drug Price Forecast by End User/Segment
13 Global Hemophilia A Drug Market Forecast by Region/Country
13.1 Global Hemophilia A Drug Market Forecast by Region (2022-2027)
13.1.1 Global Hemophilia A Drug Sales Volume Forecast by Region (2022-2027)
13.1.2 Global Hemophilia A Drug Sales Value Forecast by Region (2022-2027)
13.2 North America Market Forecast
13.3 Europe Market Forecast
13.4 Asia Pacific Market Forecast
13.5 Central & South America Market Forecast
13.6 Middle East & Africa Market Forecast
14 Key Participants Company Information
14.1 mAbxience SA
14.1.1 Company Information
14.1.2 Hemophilia A Drug Product Introduction
14.1.3 mAbxience SA Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.1.4 SWOT Analysis
14.2 LFB SA
14.2.1 Company Information
14.2.2 Hemophilia A Drug Product Introduction
14.2.3 LFB SA Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.2.4 SWOT Analysis
14.3 Immusoft Corp
14.3.1 Company Information
14.3.2 Hemophilia A Drug Product Introduction
14.3.3 Immusoft Corp Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.3.4 SWOT Analysis
14.4 Idogen AB
14.4.1 Company Information
14.4.2 Hemophilia A Drug Product Introduction
14.4.3 Idogen AB Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.4.4 SWOT Analysis
14.5 Green Cross Corp
14.5.1 Company Information
14.5.2 Hemophilia A Drug Product Introduction
14.5.3 Green Cross Corp Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.5.4 SWOT Analysis
14.6 Expression Therapeutics LLC
14.6.1 Company Information
14.6.2 Hemophilia A Drug Product Introduction
14.6.3 Expression Therapeutics LLC Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.6.4 SWOT Analysis
14.7 EpiVax Inc
14.7.1 Company Information
14.7.2 Hemophilia A Drug Product Introduction
14.7.3 EpiVax Inc Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.7.4 SWOT Analysis
14.8 Dimension Therapeutics Inc
14.8.1 Company Information
14.8.2 Hemophilia A Drug Product Introduction
14.8.3 Dimension Therapeutics Inc Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.8.4 SWOT Analysis
14.9 DBV Technologies SA
14.9.1 Company Information
14.9.2 Hemophilia A Drug Product Introduction
14.9.3 DBV Technologies SA Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.9.4 SWOT Analysis
14.10 CSL Ltd
14.10.1 Company Information
14.10.2 Hemophilia A Drug Product Introduction
14.10.3 CSL Ltd Hemophilia A Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
14.10.4 SWOT Analysis
14.11 Chugai Pharmaceutical Co Ltd
14.12 Catalyst Biosciences Inc
14.13 Bioverativ Inc
14.14 BioMarin Pharmaceutical Inc
14.15 Bayer AG
15 Conclusion
16 Methodology
no record found